For example, four genes (i.e., GRB2, HDAC1, HDAC2, and TP53) identified in the chronic myeloid leukemia pathway are known to be distinguish AML from ALL, indicating that other genes in this module might also be potential biomarkers for AML. This evidence concerns the gene HDAC2 and chronic myelogenous leukemia, BCR-ABL1 positive.